HOME >> BIOLOGY >> NEWS
Over the edge: New therapeutic strategy takes advantage of stressed cancer cells

A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves. Scientists have successfully exploited the oxidative stress common in cancer cells to preferentially kill malignant cells. This approach has the therapeutic advantage of selectively targeting cancer cells while exhibiting minimal toxicity in normal cells. The research is published in the September 2006 issue of the journal Cancer Cell, published by Cell Press.

Most cancer cells exhibit overproduction of reactive oxygen species (ROS), which is thought to provide favorable conditions for cancer cell growth, genetic instability, and survival. Dr. Peng Huang from the Department of Molecular Pathology at the University of Texas M.D. Anderson Cancer Center and colleagues hypothesized that increased ROS generation may also make cancer cells highly vulnerable to exogenous ROS-modulating agents that would not be toxic to normal cells with low ROS output.

The researchers examined the ability of a naturally occurring compound called -phenylethyl isothiocyanate (PEITC), which is known to modulate cellular antioxidant pathways, to push cancer cells to even higher ROS levels that result in cell death. Oncogenically transformed cells exhibited high basal ROS levels and were more sensitive to PEITC than nontransformed cells. PEITC interfered with a specific antioxidant system that the cancer cells relied on to maintain a ROS balance that was compatible with survival. Treatment with PEITC led to further ROS accumulation that caused massive death of cancer cells but no cytotoxicity in normal cells. Importantly, PEITC also significantly prolonged survival in an animal model of human cancer.

"Our study suggests that the intrinsic oxidative stress in cancer cells associated with oncogenic transformation provides a basis for developing therapeutic strategies to preferentially kill cancer cell
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
11-Sep-2006


Page: 1 2

Related biology news :

1. On the cutting edge: Carbon nanotube cutlery
2. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
3. From clinical cancer research: rethinking therapeutic cancer vaccine trials
4. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
5. New therapeutic insight into duchenne muscular dystrophy
6. Small molecule derived from Rb2/p130 could act as cancer therapeutic
7. Sphingolipids with therapeutic ends
8. New therapeutic target for Alzheimers could lead to drugs without side effects
9. VBI research offers potential route to diabetes therapeutics
10. Quiet revolution may herald new RNA therapeutics
11. Scientists discover two-component lantibiotic with therapeutic potential

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/14/2020)... ... 2020 , ... Enso Discoveries is proud to announce Trey ... the newly launched histopathology laboratory in addition to the national division of veterinary ... and Rebound PRF devices into both national and international veterinary supply distributors, Pittman ...
(Date:4/9/2020)... Calif. (PRWEB) , ... April 08, 2020 , ... ... the Dr. Oligo 768XLc, the most commercially advanced platform for high throughput nucleic ... fits the needs of organizations focused on diagnostic and therapeutic applications for various ...
(Date:4/7/2020)... ... April 06, 2020 , ... An early ... BLX immediate dental implant system by Straumann®. Combining the expertise of a ... able to have a tooth extracted and a dental implant placed in the ...
Breaking Biology News(10 mins):
(Date:4/22/2020)... ... April 21, 2020 , ... ... for determination of FXIII. , Aniara Diagnostica, a multi-national distributor of diagnostic and ... today’s highest standards for product quality and cost-efficient delivery. , For ...
(Date:4/7/2020)... (PRWEB) , ... April 06, 2020 , ... Gateway ... future children, reached 200,000 SneakPeek Early Gender DNA Tests sold in March, ... was launched as an ecommerce product, where a mom could order her kit ...
(Date:4/1/2020)... AUSTIN, Texas (PRWEB) , ... March 30, 2020 ... ... MD (APMD) and telehealth developer Reliant Immune Diagnostics (RID), formed earlier this year ... the COVID-19 pandemic by creating in-home tests for COVID-19. Company officials are currently?awaiting ...
(Date:4/1/2020)... ... March 31, 2020 , ... Bedoukian ... signing of a Joint Development Agreement that builds on each company’s expertise in ... global leader in the supply of high-quality insect pheromones as well as flavors ...
Breaking Biology Technology:
Cached News: